Researchers puzzle over whether HIV accelerates cancer progression

Liz Highleyman
Published: 16 April 2018

Although people living with HIV may be diagnosed with cancer at an earlier stage because they get more consistent care than the general population, it is also possible that a higher likelihood of late cancer diagnosis among people with HIV is an indication that HIV may accelerate cancer progression, according to research presented at the 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018) last month in Boston.

Prior research has shown that people with HIV are more likely to develop several types of cancer, though for other types there appears to be no difference between HIV-positive and HIV-negative people. The increase in risk among people with HIV is especially notable for virus-linked cancers such as cervical and anal cancer (caused by human papillomavirus), liver cancer (caused by hepatitis B and C) and certain types of lymphoma (associated with Epstein-Barr virus).

Keri Calkins and colleagues from Johns Hopkins University in Baltimore compared outcomes among HIV-positive people with cancer enrolled in the Johns Hopkins HIV Clinical Cohort and the mostly HIV-negative general population represented in the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database.

To date, there has been limited research on disease progression and outcomes among HIV-positive people with cancer. Some studies suggest that people with HIV are diagnosed with cancer later, are less likely to be treated and have poorer survival, but data have been inconsistent, they noted as background. Greater immune suppression may result in more aggressive cancer and may make cancer treatment less tolerable. HIV-positive people are also more likely to have risk factors such as smoking and viral co-infections that affect cancer risk and outcomes.

The researchers compared 254 people newly diagnosed with their first cancer (excluding Kaposi sarcoma) between 1997 and 2014 and nearly 1.9 million people diagnosed with first cancers of the same types in the SEER database between 2000 and 2014.

In the Johns Hopkins cohort, 69% were men, 78% were black and the median age at diagnosis was 50 years. The most common cancers were non-Hodgkin lymphoma (21%), lung cancer (17%), liver cancer (9%), Hodgkin lymphoma (7%), prostate cancer (7%), breast cancer (6%) and anal cancer (6%).

People in the Johns Hopkins cohort were substantially more likely than those in the SEER database to be diagnosed with localised cancer (30% vs 6%, for a probability difference of 24%), after adjusting for age, sex, race/ethnicity, year of diagnosis and cancer type. Localised cancer generally indicates that it is at an early stage, though some cancers progress slowly and can still be localised years after they develop.

Likewise, the chances of having cancer spread to distant parts of the body were also higher in the HIV-positive group (45% vs 9%, for a probability difference of 36%). Distant metastasis is typically an indication of late-stage cancer, though some cancers progress rapidly and can spread throughout the body soon after they arise.

Overall, people in the Johns Hopkins cohort and those in the SEER database had a similar likelihood of receiving any kind of cancer treatment (83% vs 87%, respectively). This remained the case when looking at people with CD4 counts above or below 200 cells/mm3, the latter indicating substantial immune suppression.

HIV-positive people with cancer had overall shorter survival – by 5.4 months – than those in the general population within the first 5 years after a cancer diagnosis when adjusting for demographic factors, year of diagnosis and cancer type. However, the difference was no longer statistically significant after accounting for cancer stage and treatment.

The difference in survival was more pronounced – a reduction of 11.7 months – among HIV-positive people with a low CD4 count. This difference was smaller (a reduction of 6.8 months) but remained significant after adjusting for cancer stage and treatment.

Notably, there was no difference in survival among HIV-positive people with CD4 counts above 200 cells/mm3, which should now be the status of almost everyone taking modern antiretroviral therapy.

"People with HIV are more likely to be diagnosed with cancer at earlier and later stages than the general US population, suggesting that HIV may contribute to faster progression and that engagement in HIV care may improve earlier detection," the researchers concluded.

Reference

Calkins K et al. Cancer stage, treatment, and survival comparing HIV clinic enrollees and SEER. 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018), Boston, abstract 652, 2018.

View the abstract on the conference website.

Download the presentation poster from the conference website (PDF).

Related news selected from other sources

More editors' picks on cancer >

NAM's news coverage of the 2018 Conference on Retroviruses and Opportunistic Infections has been supported by a grant from Gilead Sciences Europe Ltd.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.